v3.25.1
Segment Information - Schedule of Reconciliation to the Consolidated Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Revenues $ 14,063 $ 7,902
Cost of revenues 655 1,269
Restructuring (513) (597)
Net loss (62,214) (108,483)
Corporate and Reconciling Items [Member]    
Segment Reporting Information [Line Items]    
Revenues 14,063 7,902
Cost of revenues 655 1,269
Non-program expenses 19,258 22,131
People and staff augmentation 37,851 45,910
Restructuring 513 (597)
Other segment items 1,685 4,507
Net loss (62,214) (108,483)
Corporate and Reconciling Items [Member] | zuranolone (ZURZUVAE) [Member]    
Segment Reporting Information [Line Items]    
Total program expenses 12,010 5,257
Corporate and Reconciling Items [Member] | SAGE-319 [Member]    
Segment Reporting Information [Line Items]    
Total program expenses 1,667 953
Corporate and Reconciling Items [Member] | SAGE-324 [Member]    
Segment Reporting Information [Line Items]    
Total program expenses (837) 3,831
Corporate and Reconciling Items [Member] | Dalzanemdor [Member]    
Segment Reporting Information [Line Items]    
Total program expenses (30) 23,668
Corporate and Reconciling Items [Member] | Other research and development programs [Member]    
Segment Reporting Information [Line Items]    
Total program expenses $ 3,505 $ 9,456